Date: 2018-01-05
Type of information: Nomination
Compound: chief financial officer
Company: Aduro Biotech (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 5, 2018, Aduro Biotech announced that Jennifer Lew has been promoted to chief financial officer. Ms. Lew, who previously served as the company's senior vice president of finance, will oversee the company's global finance operations, including accounting, planning, and investor relations functions. Separately, Gregory W. Schafer will be stepping down from his position as chief operating officer in early March and has agreed to continue as a consultant to the company to facilitate a smooth transition of responsibilities.
Jennifer Lew joined Aduro in October 2013 and has served as our Senior Vice President of Finance since January 2015 . Prior to joining Aduro, from 2004 to 2013, Ms. Lew held various positions of increasing responsibility at Dynavax Technologies , culminating as Vice President of Finance and Principal Accounting Officer responsible for all accounting and finance operations. Earlier in her career Ms. Lew served as Assistant Controller and Director of Finance at QRS Corporation , a publicly-held technology company, and was a member of the audit practice at Ernst & Young. Ms. Lew earned a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).
Financial terms:
Latest news:
Is general: Yes
